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Abstract
Objective. Acid antisecretory agents are used for the prophylaxis of cancer chemotherapy (CT)-induced gastrointestinal
(GI) mucositis. Although these drugs seem to be clinically beneficial, data on their effects on the GI mucosal defense during
CT treatment are scant. The objective of this study was to compare the effects of omeprazole, lansoprazole, and lafutidine
on mucin, a major mucus component, during 5-fluorouracil (5-FU) treatment, as a CT regimen. Material and methods.
Rats, weighing approximately 230 g, were divided into five groups. The control group was administered 0.5%
carboxymethylcellulose orally once daily for 5 days. The second, third, fourth, and fifth groups were treated with 5-FU
(50 mg/kg), 5-FU plus omeprazole (10 mg/kg), 5-FU plus lansoprazole (10 mg/kg), and 5-FU plus lafutidine (30 mg/kg) in
the same way, respectively. The rats were sacrificed on the sixth day, and their stomachs and small intestines were removed.
Using anti-mucin monoclonal antibodies, we compared the immunoreactivity in different areas of the rats’ GI tracts as well
as the mucin content. Results. Body-weight decreased in rats in the 5-FU group. Lafutidine, but neither omeprazole nor
lansoprazole, inhibited the 5-FU-induced weight loss. Mucosal damage and reduced mucin content in stomach and small
intestine were observed in rats receiving 5-FU alone. In the stomach, all antisecretory drugs caused the protective effects
against 5-FU-induced mucosal injury and alleviation of the decreased mucin accumulation. In the jejunum and ileum,
lafutidine, but neither omeprazole nor lansoprazole, ameliorated the 5-FU-induced mucosal damage and decreased mucin
accumulation. Conclusion. Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis
through the activation of GI mucus cells.
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Introduction
In 2004, the Mucositis Study Group of the Multi-
national Association of Supportive Care in Cancer
(MASCC) and the International Society for Oral
Oncology (ISOO) published the clinical practice
guidelines for the prevention and treatment of
cancer chemotherapy (CT)-induced gastrointestinal
(GI) mucositis [1,2]. The updated guidelines re-
commend either ranitidine or omeprazole for the
prophylaxis of epigastric pain after treatment with
cyclophosphamide, methotrexate, and 5-fluorouracil
(5-FU) or treatment with 5-FU with or without
folinic acid [3]. The potential utility of omeprazole
in the prevention of CT-induced gastroduodenal
injury has been clearly demonstrated by the rando-
mized trials in Europe [4,5]. In Japan, anti-ulcer
drugs such as lansoprazole and lafutidine are given
prophylactically to patients during CT treatment in
the absence of randomized controlled trials.
Although these drugs seem to be clinically beneficial
in reducing gastric acid secretion [6,7], data on their
effects on the GI mucosal defense mechanisms
during CT treatment are scant.
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ered to be one of the principal factors in the
physiological defense of the GI mucosa. In our
previous studies, we have reported quantitative
and qualitative changes in GI mucin in experimen-
tal animals treated with various drugs including
5-FU, and demonstrated its importance in the
GI mucosal barrier [811]. We have also establis-
hed several monoclonal antibodies (mAbs) that
react with mucin synthesized and secreted from
specific mucus-producing cells of the rat GI mucosa
[12,13].
The first objective of the present study was to
compare the efficacy of omeprazole, lansoprazole,
and lafutidine against 5-FU-induced rat GI mucosal
injury. Secondly, we sought to evaluate their effects
on mucin accumulation in different areas of the GI
tract.
Material and methods
Animals and drug treatment
Seven-week-old male Wistar rats purchased from
CLEA-Japan (Tokyo, Japan) were used in this
study. These animals were housed in our animal
care facility for 12 weeks while body-weight
stabilized. The animals were housed in individual
cages with raised mesh bottoms and in a tempera-
ture- and humidity-controlled environment with
a 12-h darklight cycle (18000600 h dark cycle).
At the beginning of the experimental period, the
animals were weighed after fasting for 24 h.
During the below-mentioned treatment, rats were
given food and water ad libitum. After 24 h of
food deprivation following final administration of
drugs, the animals were again weighed, sacrificed,
and their stomachs, proximal and distal small
intestines (corresponding to the jejunum and ileum,
respectively) were removed. The present study
was conducted according to the guidelines of the
Animal Laboratory Center of Kitasato University
School of Medicine.
5-FU was administered orally by gavage (50 mg/
kg) once daily for 5 days. Anti-ulcer drugs used
were omeprazole, lansoprazole (Sigma-Aldrich
Corp., St. Louis, Mo., USA), and lafutidine (Taiho
Pharm. Co. Ltd., Tokyo, Japan). All drugs were
suspended in 0.5% carboxymethylcellulose (CMC)
solution and prepared immediately before use. Each
anti-ulcer drug (omeprazole 10 mg/kg; lansoprazole
10 mg/kg; lafutidine 30 mg/kg) was given orally
30 min before the respective 5-FU administration.
Control animals received 0.5% CMC instead of
5-FU and anti-ulcer drugs.
Histological examination
Specimens of each tissue were immediately fixed for
3 h in freshly prepared Carnoy’s solution following
the method described elsewhere [14]. After fixation,
the materials were dehydrated through ethanol,
cleared in xylene and embedded in paraffin. From
these specimens, 3-mm paraffin sections were pre-
pared for immunostaining with anti-mucin mAbs.
Immunohistochemical staining was done using
the avidin-biotin peroxidase method and an LSAB2
Kit (Dako, Carpinteria, Calif., USA). Briefly, en-
dogenous peroxidase activity was blocked with
0.3% H2O2, and then the tissue was sequentially
incubated with 10% (v/v) normal swine serum, the
anti-mucin mAb (RGM21, RGM26, PGM34),
biotinylated anti-mouse immunoglobulins, strepta-
vidin horseradish peroxidase (HRP), and 0.02%
3,3-diaminobenzidine in 50 mM Tris-HCl, pH 7.6,
containing 0.005% H2O2. The counterstaining was
done with hematoxylin. The immunohistochemical
reactivity of each of the mAbs was observed using an
optical microscope. As previously described [11,12],
the immunohistochemical reactivities of RGM21
and RGM26 were located in the surface epithelial
mucus cells of the rat corpus and antral mucosa,
respectively. Regarding PGM34, it was recently
shown that the epitope of this mAb was a specific
sulfated oligosaccharide of the mucin molecule.
This mAb stains all the goblet cells of rat small
intestine [13].
Biochemical examination
Specimens from each tissue were lyophilized and
powdered for extraction of mucin by the previously
described method [8]. Each sample was suspended
in 50 mM Tris-HCl, pH 7.2, containing 2% Triton
X-100 (Triton-Tris buffer), homogenized and then
incubated at 378C for 1 h. After centrifugation at
8000 g for 30 min at 48C, the supernatant was
collected and an aliquot was applied to a Bio-Gel
A-1.5 m column, and eluted with the Triton-Tris
buffer. The void volume fraction (Fr-1) monitored
by hexose measurement was collected as mucin.
Hexose content in this fraction was measured by
the phenol-sulfuric acid method using galactose as
the standard. Mucin content (Fr-1 hexose value)
was expressed as micrograms of hexose per tissue.
Statistical analysis
The difference in the mean values among the groups
was analyzed by one-way ANOVA with Scheffe’s
test; a p-value of less than 0.05 was considered to
indicate statistical significance.
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Body-weight change
The changes in the body-weight of the rats in each
experimental group are recorded in Table I. During a
6-day period, a body-weight gain was seen in rats
of the control group, whereas a weight loss was
found in the animals given 5-FU orally at a dose of
50 mg/kg once daily for 5 consecutive days. There
were virtually no changes in the weights of rats
administered 5-FU with either omeprazole or lanso-
prazole. There was a slight tendency toward an
increase in the lafutidine plus 5-FU group, indicat-
ing that lafutidine inhibits 5-FU-induced body
weight loss.
Changes in immunoreactivity and mucin content of the
gastric mucosa
Figure 1 shows the morphological changes in corpus
and antral mucosae after the treatments. In the
control rat, gastric surface epithelial mucus cells
were strongly stained with anti-mucin mAbs
(RGM21 and RGM26, Figure 1A and F, respec-
tively). Treatment with 5-FU caused gastric mucosal
damage restricted to the superficial epithelium
[11]. This was characterized by significant decreases
in the RGM21- and RGM26-immunoreactivities
in the corpus and antrum, respectively, when com-
pared with the individual control (Figure 1B, G).
In contrast, significant observable damage could
rarely be found in the gastric mucosae of the animals
with the combined application of 5-FU and ome-
prazole, lansoprazole, or lafutidine (Figure 1CE,
HJ).
Figure 2 shows the effect of omeprazole, lanso-
prazole, or lafutidine treatment on the corpus mucin
content in the 5-FU-induced gastric mucosal da-
mage expressed as the Fr-1 hexose value. In the
corpus of the rats treated with 5-FU, the mucin
content was significantly decreased to 57.6% of
the control. The 5-FU-induced mucin reduction
was inhibited by the combination treatment of
omeprazole, lansoprazole, or lafutidine.
Changes in immunoreactivity and mucin content of the
small-intestinal mucosa
Figure 3 shows the morphological changes in the
small-intestinal mucosa after treatments. In the
control rats, immunohistochemical reactivity for
PGM34 could be detected in the goblet cells, as
well as the surface mucus gel layer, in the jejunum
and ileum (Figure 3A, F). As shown in Figure 3B
and G, 5-FU treatment caused a marked decrease
in villus height and a remarkable reduction in
the number of PGM34-positive goblet cells. In
the animals treated with a combination of 5-FU
and lafutidine, significant observable damage could
rarely be found in the sections of the jejunal or ileal
mucosa (Figure 3E, J), whereas neither omeprazole
(Figure 3C, H) nor lansoprazole (Figure 3D, I)
was shown to prevent the 5-FU-induced intestinal
mucosal damage.
Figure 4 shows the comparison of the effects of
the anti-ulcer drugs on the small-intestinal mucin
contents in the 5-FU-induced mucosal damage.
A decrease in the mucin content of the jejunum
and ileum was observed after treatment with 5-FU
(29.6% and 42.9% of the control mucin content,
respectively). Lafutidine pretreatment significantly
inhibited the 5-FU-induced mucin reduction in the
jejunum and ileum mucin (75.8% and 66.1% of the
control mucin, respectively), whereas no significant
change could be detected in the mucin content in the
small intestine by the 5-FU treatment with either
omeprazole or lansoprazole.
Discussion
Using the original anti-mucin mAbs RGM21 and
RGM26, we demonstrated the protective effects of
three anti-ulcer drugs, omeprazole, lansoprazole, and
lafutidine, against 5-FU-induced gastric mucosal
Table I. Weight changes in rats before and after the treatments.
Body Weight
n Before After
Control 9 229.8 (96.2) 256.4 (96.1)
5-FU 8 231.0 (98.7) 204.2 (910.2)
Ome5-FU 7 227.3 (917.5) 220.7 (911.8)
Lan5-FU 6 226.2 (95.3) 220.2 (94.8)
Laf5-FU 9 238.1 (96.2) 245.0 (911.3)
Mean (9SD); *pB0.05; 5-FU5-fluorouracil; Omeomeprazole; Lanlansoprazole; Laf
lafutidine.
Drugs for 5-FU-induced GI mucositis 533injury of the rat. From the randomized controlled
studies, Sartori et al. [4,5] documented that the
strong and prolonged suppression of gastric acid
secretion by omeprazole was effective in preventing
and reducing CT-induced gastroduodenal mucosal
injury, suggesting an important prophylactic role of
the inhibition of acid secretion. Both lansoprazole
and lafutidine possess a potent and long-lasting
gastric antisecretory effect in humans [6,7]. In the
rat models, each drug at the dose used in this study
has been shownsufficiently to decrease both the basal
and the stimulated acid secretion [1518]. Our
results strongly support the clinical studies showing
that the acid-inhibitory drugs such as proton-pump
inhibitors (PPIs) and H2-blockers are effective in
reducing the frequency of gastric mucosal injury
and upper GI symptoms caused by CT treatment
[4,5,19].
In the stomach, mucin is a key element in
protecting the gastric epithelium against various
irritants [8,10,20]. Changes in gastric mucin content
have been shown to occur in association with the
oral administration of certain chemical agents in-
cluding aspirin and 5-FU [8,10,11]. In this study, a
significant decrease in the mucin content of corpus
mucosa was noted after oral administration of 5-FU
at a dose of 50 mg/kg once daily for 5 consecutive
days. Our most notable finding was that the mucin
content did not decrease in animals given each of the
anti-ulcer drugs used in this study. Accumulation
of mucin in the gastric mucosa is closely related
to mucosal protective capability [810]. We have
already reported that lafutidine, independent of its
histamine H2-receptor antagonistic property, exerts
a stimulant activity in the mucin accumulation and
the protective effect against necrotizing-agent-in-
duced gastric mucosal damage in the rat [9]. More-
over, our recent study showed that lafutidine, given
at clinical dosages, not only inhibits acid secretion
but also strengthens the mucus barrier of the human
gastric mucosa [21]. The preventive effects of three
anti-ulcer drugs against the 5-FU-induced gastric
mucosal injury might also be associated with the
non-acid inhibitory mechanism including mucosal
defensive factors.
As we have previously demonstrated [11], oral
administration of 5-FU caused the remarkable
Figure 1. Immunostaining of the gastric corpus (AE) and antral (FJ) mucosae with anti-mucin monoclonal antibodies. Gastric tissues
were obtained from control rats (A, F), rats treated with 5-ﬂuorouracil (5-FU) alone (B, G), rats treated with omeprazole (Ome 5-FU (C,
H), rats treated with lansoprazole (Lan)5-FU (D, I), and rats treated with lafutidine (Laf)5-FU (E, J). Notice that surface epithelial
mucus cells in the corpus show positive staining with RGM21, and those in the antrum show positive staining with RGM26. Original
magniﬁcation25.
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Figure 2. Inﬂuence of acid antisecretory agents on the gastric
corpus mucin accumulation in the 5-FU-induced gastric mucosal
damage. Fr-1 hexose values corresponding to mucin content are
expressed as micrograms of hexose per rat and represent means9
SD. Abbreviations: 5-FU5-ﬂuorouracil; Omeomeprazole;
Lanlansoprazole; Laflafutidine. n69 (each group); *pB
0.05.
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the mucin content in the rat small intestine, espe-
cially in the jejunum. Here we report on a preventive
effect of lafutidine on 5-FU-induced alteration in
the rat intestinal mucus. Although the protective
property of intestinal mucin has received limited
attention compared with gastric mucin [22], our
results suggest that lafutidine may be extremely
useful in reducing CT-induced GI mucosal damage.
Recent studies have documented the prophylactic
effect of this drug on indomethacin-induced small-
intestinal ulcers in rats [23,24]. Moreover, our study
showed that lafutidine had an effect on body-weight
loss in the animals treated with 5-FU. Although
accurate measurement of either food intake or fecal
output was not done in our investigation, lafutidine
appeared to prevent the 5-FU-induced hypophagia
and ingestion. These findings should be confirmed
in future large randomized controlled clinical trials
of lafutidine during CT treatment.
Anti-neoplastic drugs may cause severe damage to
normal cells in organs with a high cellular turnover.
Because gastric and intestinal epithelia have a
high growth fraction [25], the potential risk of
CT-induced injury is high. Therefore, it is possible
that reduction of CT-induced GI injury may be
related to a reduction in the growth-inhibitory ability
of anti-cancer agents. However, to our knowledge,
there are no previous reports to show that the
anti-ulcer drugs used in this study will lead to a
decreased anti-tumor efficacy in cancer CT treat-
ment. Dilloway & Lant [26] reported that a
non-imidazole-based H2-blocker did not cause any
Figure 3. Immunostaining of the rat jejunal (AE) and ileal (FJ) mucosae with anti-mucin monoclonal antibody PGM34. Small-bowel
tissues were obtained from control rats (A, F), rats treated with 5-ﬂuorouracil (5-FU) alone (B, G), rats treated with omeprazole (Ome)5-
FU (C, H), rats treated with lansoprazole (Lan)5-FU (D, I), and rats treated with lafutidine (Laf)5-FU (E, J). Notice that goblet cells in
the jejunum and ileum show positive staining with PGM34. Original magniﬁcation25.
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Figure 4. Inﬂuence of acid antisecretory agents on the jejunal (A)
and ileal (B) mucin accumulation in the 5-FU-induced small-
bowel mucosal damage. Fr-1 hexose values corresponding to
mucin content are expressed as micrograms of hexose per rat and
represent means9SD. Abbreviations: 5-FU5-ﬂuorouracil;
Omeomeprazole; Lanlansoprazole; Laflafutidine. n69
(each group); *pB0.05.
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rat and monkey, suggesting that lafutidine could
not reduce the 5-FU blood levels. In the preliminary
study using a Yoshida sarcoma-bearing rat model,
lafutidine had no influence on the anti-tumor activity
of TS-1 (30 mg/kg p.o.), a prodrug of 5-FU (data
not shown). Our previous report showed that
lafutidine directly stimulated the mucin production
in the rat mucus cells [27,28]. Thus, the preventive
effect of lafutidine against 5-FU-induced intestinal
damage may be attributed to the increased produc-
tion of mucin by the goblet cells that remained alive
after 5-FU treatment.
Omeprazole and lansoprazole have been shown to
ameliorate intestinal mucosal damage induced by
indomethacin or ischemia-reperfusion in rats, via the
action being dependent on their anti-inflammatory
and anti-oxidative responses [2931]. In this study
omeprazole and lansoprazole failed to alleviate the
changes in both the morphological defects and
mucin contents in intestinal mucosae of rats treated
with 5-FU. We previously found that omeprazole
had no effect on mucin biosynthesis in the rat gastric
mucosa [27]. These findings suggest that the ome-
prazole and lansoprazole utilized in this study could
not promote the goblet mucus cell function.
Although further studies are needed to clarify the
detailed mechanism for 5-FU-induced intestinal
injury, the activation of the goblet cells, if appro-
priately manipulated, might lead to more effective
prevention of 5-FU-induced GI mucositis.
To summarize, we present two important research
findings. First, oral administration of omeprazole,
lansoprazole, and lafutidine caused the protective
effects against 5-FU-induced gastric mucosal injury
through alleviation of the decreased mucin accumu-
lation in the rat stomach. Second, lafutidine amelio-
rated the intestinal mucosal damage and the
decreased body-weight gain induced by 5-FU treat-
ment, raising the possibility of a more effective
prevention of CT-induced GI mucositis.
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